All News

Zimmer Biomet Announces FDA Clearance for Compatibility of Nexel™ Total Elbow and Comprehensive® Segmental Revision System

WARSAW, Ind., March 3, 2016 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, is pleased to announce that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the compatibility of the Nexel™ Total Elbow System with the Comprehensive® Segmental Revision System (SRS).  […]

Cells from cow knees used to grow new cartilage tissue in laboratory

In a bid to develop a new method for cartilage tissue engineering, researchers at Umeå University in Sweden have successfully used cartilage cells from cow knee joints. By creating a successful method with conditions conducive to growing healthy cartilage tissue, the findings could help lead to a new treatment cure for osteoarthritis using stem-cell-based tissue […]

PRINCIPAL CAUSES FOR HOSPITAL READMISSION IDENTIFIED

Biloine W. Young   What are the reasons for hospital readmission following hip and knee joint replacement surgeries? To find out a group of physicians in Canada examined a national database of more than 58,000 hip and knee replacement surgeries and published their results in The Journal of Arthroplasty. According to Brad Tritle, writing in […]

Vivex Biomedical, Inc. and Arthrex, Inc. Enter into Long Term Agreement

MARIETTA, Ga., March 31, 2016 /PRNewswire/ — Vivex Biomedical, Inc. and Arthrex Inc. have signed a new long-term agreement that strengthens the partnership between a leading provider of proprietary biologics and a premier innovator of orthopedic surgical solutions. The multi-year commitment reinforces the vision shared by Vivex Biomedical and Arthrex to progress clinical, surgical and therapeutic […]

510(k) Clearance “Corrected” 19 Years after Original Clearance

By Jeffrey N. Gibbs & Allyson B. Mullen   Imagine that you were working at a device company and you received a letter today from FDA saying that FDA was “correcting” the FDA clearance you received nineteen (19 – that is not a typo) years ago.  You would probably think about all the things that […]

East Bay Sports Medicine Joins Muir Orthopaedic Specialists

CONCORD, Calif., March 29, 2016 (GLOBE NEWSWIRE) — East Bay Sports Medicine has joined Muir Orthopaedic Specialists to provide a larger network of service offerings to the Bay Area community. Practicing under the Muir Orthopaedic Specialists (MOS) name, East Bay Sports Medicine’s (EBSM’s) office location in Concord adds a fifth MOS location to their footprint […]

Minimally Invasive VCF Devices- Multiple applications will Fuel the Market during 2016-2021

One of the key factors contributing to this market growth is the increasing prevalence of osteoporosis. The Global Minimally Invasive VCF Devices market has also been witnessing an increased focus on reduced risk of cement leakage by vendors. However, the high cost of VCF surgeries could pose a challenge to the growth of this market. […]

A 2016 Update of Product Pipeline Analysis, Amedica Corporation (AMDA): MarketResearchReports.biz

Albany, NY — (SBWIRE) — 03/30/2016 — A very detailed and unique market research report has been recently featured on the expanding market research report database of MarketResearchReports.biz. The report presents an expansive account of the portfolio of pipeline products of Amedica Corporation, a U.S.-based biomaterial company that develops, produces, and sells interbody fusion devices […]

Minimally invasive surgical treatment of spondylolysis in sportsmen and sportswomen

By: Nick Birch and David Harrison Spondylolysis – a stress fracture of the pars interarticularis – is a common cause of low back pain in children and adolescents, particularly those who are engaged in athletic pursuits [1]. In the Caucasian population, 4.4 per cent of children have pars fractures by the age of six, rising to 6 […]

Mesoblast Cell Therapy Shows Disease Modifying Effects on Knee Osteoarthritis

NEW YORK and MELBOURNE, Australia, April 01, 2016 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that results from its Phase 2a trial in patients with post-traumatic knee injury to the anterior cruciate ligament (ACL) showed that a single intra-articular injection of its mesenchymal precursor cell (MPC) product candidate, MPC-75-IA, resulted in improvement in pain, function, […]

© 2025 MedDeviceJobs.com Powered by Careerleaf
v.4.6.1